A Dialogue With Corporate Counsel: Skadden’s Ninth Annual Pharmaceutical and Medical Device Seminar

Skadden, Arps, Slate, Meagher & Flom LLP

On October 22, 2019, Skadden hosted our Ninth Annual Pharmaceutical and Medical Device Enforcement and Litigation Seminar in New York, which focused on U.S. enforcement issues companies face throughout the industry. The key takeaways from this panel are summarized below.

DOJ and OIG Enforcement Update

Panelists: John Bentivoglio and Jennifer Bragg, Skadden Health Care and Life Sciences

The panelists provided an overview of recent U.S. Department of Justice (DOJ) enforcement actions, explaining that opioids are arguably the largest area of focus. The DOJ also has focused on regulating drug prices in a number of ways, including by bringing enforcement actions against companies providing co-pay support to patients through independent charitable foundations. Further, panelists recounted that the DOJ has used enforcement actions with allegedly egregious conduct to try new enforcement tools, including RICO charges, undercover agents and tape recordings.

Regarding 2019 settlements, panelists explained that the DOJ’s primary enforcement tool, including in civil-only resolutions, was the Anti-Kickback Statute (AKS). Panelists noted that the DOJ has retreated from prosecuting purely off-label claims. Rather, it has used a “refined” off-label cause of action to investigate the provision of false or misleading information and violations of Risk Evaluation and Mitigation Strategy (REMS) requirements. Most 2019 settlements were small, civil-only and related to financial relationships with physicians.

Panelists highlighted recent co-pay enforcement actions in which the DOJ continued to allege that companies inappropriately provided co-pay support to patients through independent charitable foundations. Review of settlements and press releases revealed that the government frequently mentions high drug costs, viewing these support services as elaborate schemes to support drug prices. Panelists stated that many of the activities featured in the co-pay settlements are not problematic in and of themselves, but can be problematic once combined. While the settlements and resulting corporate integrity agreements provide companies some guidance for structuring relationships with charitable foundations, panelists observed that companies remain without guideposts for all aspects of the relationships, including how to set an appropriate donation budget without commercial involvement.

As stated in the Office of the Inspector General’s (OIG) 2003 Compliance Program Guidance for Pharmaceutical Manufacturers, product support services alone do not implicate the AKS if they are structured properly. Panelists stated that the 2003 guidance was reaffirmed in recent DOJ filings moving to dismiss qui tam actions which asserted that nurse-educator services were inappropriate. Panelists explained that the DOJ’s filings were a positive development for manufacturers, reinforcing the legitimacy of certain support services, such as toll-free hotlines. Panelists emphasized, however, companies must consider not only what services they are providing to patients, but what services they are, in effect, rendering to physicians’ offices.

Addressing prospective areas of risks, panelists explained that future DOJ enforcement actions are likely to grow from today’s environment. Speaker bureaus and payments to physicians remain the single largest area of risk for pharmaceutical companies. In particular, companies should keep in mind that data is increasingly becoming available to the government and relators, and that the DOJ is proactively analyzing data on payments and prescriptions. In addition, panelists noted, companies should expect to see increased enforcement activity related to product quality issues.

Advertising, Promotions and Trade Complaints

Panelists: Karen Corallo, Skadden Health Care and Life Sciences; Anthony Dreyer, Skadden Intellectual Property Litigation; and Michelle Kloecker, Director and Pharmaceutical Counsel, Novartis Pharmaceuticals Corporation, Global Oncology

The panelists first discussed ways in which companies can bring forth actions against competitors for purportedly false or misleading advertisements. Specifically, they highlighted litigation of false advertising claims through both federal courts under the Lanham Act and proceedings with the National Advertising Division (NAD).

The panelists explained that in light of the Supreme Court’s decision in POM Wonderful LLC v. Coca-Cola Co., 134 S. Ct. 2228 (2014), compliance with the Federal Food, Drug, and Cosmetic Act (FDCA) does not immunize the content of labels from false advertising challenges under the Lanham Act. Rather, a false advertising claim may be brought if a claim is literally false, literally false by necessary implication (i.e., the context of communication conveys only one message and that message implies a false message) or misleading. A claim is misleading if it conveys an implied message and deceives a portion of the recipients. Typically, if over 20% of surveyors are confused by a claim, the claim is actionable as “misleading.”

The panelists provided an overview of the pleading requirements to support a violation of the Lanham Act. They emphasized that the claim must be made in connection with commercial advertisements, and the burden generally falls on the challenger to show that a statement is false. While claims made to investors are generally not actionable, the SEC is likely to scrutinize such statements. On the issue of damages, the panelists explained that circuit courts are split as to whether a plaintiff must prove willfulness to obtain disgorgement. This split is likely to be resolved, as the Supreme Court has granted certiorari this term in Romag Fasteners v. Fossil, Dkt. No. 18-1233.

Panelists noted that the case law is unclear as to whether consumer survey evidence is necessary to meet the Iqbal/Twombly pleadings standard. Although many courts have held that survey evidence is not needed at the district court stage and anecdotal evidence can assist a plaintiff in surviving a motion to dismiss, the U.S. Court of Appeals for the Tenth Circuit held that consumer survey evidence may be necessary by affirming the dismissal of plaintiff’s claim on the grounds that the complaint failed to cite any survey or other evidence that consumers were deceived by the allegedly misleading advertisement. See Drake Vincent v. Utah Plastic Surgery Society, No. 13-4146 (10th Cir. Aug. 31, 2015).

Next, panelists discussed advertising challenges through the NAD, which is administered by the Better Business Bureau (BBB) as a self-regulating sector of advertising. To initiate these proceedings, a challenger files a letter with the NAD raising reasonable questions as to whether the advertisement contains false or misleading claims. While the advertiser’s mere reasonable basis for making the claim may support its efficacy, the panelists noted that the leading question in a NAD proceeding is whether the challenged advertiser has prior substantiation for the claims it is making. The NAD relies on the U.S. Food and Drug Administration (FDA) or other relevant agencies to determine whether the claims at issue are substantiated. Unlike in actions under the Lanham Act, a NAD dispute places the burden on the challenged party.

The panelists expressed the importance for companies facing a NAD complaint to understand what facts to substantiate and what tools to use. Companies also need to involve the right people in the claims review and clearance process and bear in mind that results may be discoverable in future litigation. While participation in and compliance with NAD proceedings is voluntary, the failure of a challenged advertiser to participate or comply can lead to a referral to, or investigation by, the Federal Trade Commission (FTC).

Finally, the panelists discussed how various factors impact whether a company should challenge false advertising in the federal courts or through the NAD. These factors include time and cost, burdens of proof and risks, confidentiality, relief and enforcement. Companies must weigh the costs and risks of litigation and understand the business appetite for the time and resources that go into bringing a false advertisement challenge. Companies launching a challenge must also make sure their operations and recordkeeping is in order, as competitors will explore ways to fight back.

FDA Enforcement Update

Panelists: Jennifer Bragg and Maya Florence, Skadden Health Care and Life Sciences; and Ami Simunovich, Senior Vice President and Chief Regulatory Officer, Becton, Dickinson and Company

Panelists provided an overview of recent FDA enforcement trends. Overall, the FDA has continued to take a strong enforcement interest in the food and tobacco space, with additional focus on dietary supplements. The FDA generally takes a proactive approach to resolving compliance concerns, providing companies early feedback to prevent later enforcement action. This approach has resulted in fewer consent decrees and long-term monitoring requirements. Further, the Office of Prescription Drug Promotion (OPDP) has issued letters cautiously, and the Center for Devices and Radiological Health (CDRH) has taken little action in the promotional space.

More specifically, the FDA has increased resources at the border and is now checking imported products for 510(k) status. The FDA also has increased its use of import alerts, halting products from entering the country and affecting manufacturers’ ability to receive necessary materials from overseas suppliers. The use of import alerts has, in turn, reduced the number of seizures. Panelists also highlighted several recent FDA warning letters, and observed that the FDA continues to focus on new products and on products with higher-risk profiles.

Additionally, panelists provided an overview of recent developments within the FDA. For example, the FDA recently realigned its Office of Regulatory Affairs, replacing a geographic structure with a commodity-based structure. Panelists reported that the industry overall believes that the transition is a positive development that will facilitate information sharing. However, panelists cautioned, companies should be aware that responsibilities have shifted, and the transition has resulted in a learning curve for new offices. Additionally, the Medical Device Single Audit Program now provides a harmonized approach to allow one joint audit to cover multiple regulatory agencies’ standards, which similarly holds the promise of increased efficiency and decreased business interruptions, but the new process has still presented some challenges in its early implementation phase.

Patient and Physician Support Programs

Panelists: John Bentivoglio and Alexandra Gorman, Skadden Health Care and Life Sciences

Panelists addressed the evolving business model of pharmaceutical companies, which increasingly has grown to encompass specialty products that treat a small number of patients. This model has led to complexity in various industry relationships, allowing increased touchpoints with patients, physicians, independent charitable foundations, pharmacies and payors. In each relationship, manufacturers need to clearly understand the flows of money, assessments of value, information or promotional materials, and products involved.

Panelists explained that manufacturers are increasingly providing product support services to both physicians and patients. Although the OIG has stated that providing product support services with no substantial independent value may not implicate the AKS, little guidance has arisen since the 2003 Compliance Program Guidance for Pharmaceutical Manufacturers. Most recently, the DOJ affirmed that it supported the 2003 guidance by moving to dismiss several qui tam actions filed against manufacturers alleging that the provision of nurse educators to support both physician offices and patients resulted in a violation of the False Claims Act (FCA).

In providing reimbursement services, manufacturers not only have increased interactions with physician offices, they also receive additional flows of information about patients. When providing services, panelists explained, manufacturers need to know what actions are being taken, who is taking those actions and the relevant risks. Panelists highlighted that increased patient information flow can raise Health Insurance Portability and Accountability Act (HIPAA) concerns and noted that the DOJ has investigated and settled cases involving sales representatives reviewing patient files and inappropriately accessing patient information. Additionally, instances have been discovered of employees lying to insurance companies about patient profiles or their identities or employers in an attempt to secure reimbursement approval. Companies can reduce these risks by, among other things, making the reimbursement support function separate from sales and ensuring incentive compensation is appropriately structured to eliminate any incentive to lie or cherry pick information in discussions with insurance companies. Finally, panelists explained that manufacturers should publicize and provide reimbursement support to all offices, not merely to high prescribers.

Next, panelists explained that although enforcement of typical off-label promotion has decreased in recent years, the DOJ may begin to allege that manufacturers have caused medically unnecessary prescriptions to be submitted to federal health care programs. Specialty products are often expensive, and if a small number of physicians aggressively prescribe the specialty product, the DOJ may consider why those physicians are outliers and inquire into manufacturer activities (including speaker fees and other forms of remuneration) that may have led to such prescriptions. Manufacturers should keep in mind that they often have data, including from a company-sponsored hub, that will reveal the types of prescriptions written.

The panelists predicted that the government is likely to take an increasing interest in manufacturers’ relationships with specialty pharmacies. Often specialty pharmacies can serve as a company-sponsored hub to provide patient and physician support services. Companies should understand not only the services set forth in those contracts but also conduct back-end monitoring to see what actions the specialty pharmacies are taking.

Finally, panelists noted that a fair amount of guidance is available relating to free drug programs. The OIG and the DOJ are concerned about the use of free drug programs as starter programs that, the agencies believe, are meant to hook patients on high-cost drugs. Panelists stated that free drug programs are not the same as sample programs, and companies should keep in mind that the Prescription Drug Monitoring Act does not address anti-kickback risks.

State of the Industry: A Wall Street Perspective

Panelists: Danielle Antalffy, Andrew Berens, Ami Fadia, Jim Kelly and Richard Newitter, Managing Directors, SVB Leerink

Over the past decade, panelists reported, health care has been the third best-performing sector overall, generally outperforming the market. Drug pricing, innovation — particularly in the biotechnology space — and increased access to health care have contributed to this standing, while product recalls and DOJ investigations have impacted premiums over the years.

Panelists explained that they, as Wall Street analysts, try to understand the fundamentals behind a company so that investors can in turn know the impact of investing in company stock. Analysts often try to define a framework around an event so that investors can comprehend its potential impact and defined risks. For example, analysts will try to evaluate the contingent liabilities of a warning letter or of patent litigation and define the resulting worst-case scenario. Often, panelists shared, uncertainty is more problematic than bad news. It is difficult, for example, to predict FDA actions and their impact.

Large investment decisions are often made with imperfect information. Panelists agreed that a company maintains responsibility to frame what it knows and what it does not know, and investors want to know all the information that the company can share. Panelists encouraged companies to take a straightforward approach and provide accurate information, since giving vague, incomplete or delayed information can lead to consequences later.

The Next Frontiers: Data Privacy, HIPAA and Cybersecurity

Panelists: Maya Florence, Skadden Health Care and Life Sciences; Bill Ridgway, Skadden Litigation, Cybersecurity and Privacy; and David Bloch, Principal Legal Counsel, Medtronic

Panelists discussed the application of both health care-specific and generally applicable statutory schemes regulating data privacy and cybersecurity. With respect to HIPAA, panelists observed that historical HIPAA enforcement recoveries have been relatively modest compared to DOJ enforcement activity, and generally have involved health care providers rather than life sciences companies. Panelists speculated that this trend may change over time, as life sciences companies increasingly have access to additional patient data through activities such as reimbursement support and product support applications. Panelists also cautioned that life sciences companies may have access to more patient data than they appreciate, including data collected through clinical trials and adverse events. Panelists noted that HIPAA-related enforcement involving life sciences companies generally have involved sales representatives who mishandled or inappropriately accessed patient data to help increase drug sales, and panelists warned that these types of actions involve a high risk of reputational damage.

The FDA recently issued draft industry guidance, Content of Premarket Submissions for Management of Cybersecurity in Medical Devices, to highlight its view that cybersecurity issues now represent a known risk for medical devices and must be addressed through a manufacturer’s quality systems. Panelists then addressed the increasingly complex cybersecurity landscape, focusing on the heightened threat posed by ransomware. Panelists emphasized the need for information technology personnel, regulatory personnel and in-house counsel to be in constant communication to assess the likelihood of a compromise to company data and the severity of any perceived issue. Finally, panelists discussed the increase in cybersecurity whistleblowers, and recommended that companies examine their reporting channels for IT compliance concerns.

False Claims Act and Big Data

Panelists: Alexandra Gorman, Michael Loucks, Greg Luce, Skadden Health Care and Life Sciences; and Brad Rice, Vice President, Analysis Group

Panelists addressed the growing trend of using statistics and extrapolation from representative samples of claims to establish liability under the FCA. They reported that the use of statistics and extrapolation to establish damages in FCA cases is not a novel proposition. Courts have often accepted the discipline as an appropriate way to deal with large numbers of claims at issue after liability has been imposed. This approach is common when information may not exist otherwise, for instance, due to missing patient files or incomplete sets of claims, or when a claim-by-claim review would be too costly. Ultimately, courts are cognizant that a factfinder can decide what weight to give the extrapolated data.

Panelists also explained that less frequently, but more controversially, relators have proposed using sampling to establish FCA liability. However, the panelists noted that use of extrapolation for liability is in tension with the decision in Universal Health Servs., Inc. v. United States ex rel. Escobar, 136 S. Ct. 1989 (2016), where the Supreme Court held that a company’s misrepresentations about compliance with governing laws must be material to the government’s decision to pay in order to be actionable under the FCA. Moreover, the FCA requires a plaintiff to establish the defendant’s scienter. Panelists noted that trying to meet the Escobar standards through extrapolation from limited sets of data may be inappropriate because it does not help decipher intent.

With respect to the validity of extrapolation methods, panelists explained that best practice requires a purely random and large sample size, which may require an oversampling for certain subgroups, or potentially the use of machine learning/AI methods currently at the forefront in this area. Although relators have at times included only a selection of small subsets of data, this is a statistically flawed approach. Regardless of extrapolation methods, panelists noted the importance for companies early in proceedings to examine and, when necessary, challenge the quality of extrapolation methods in FCA investigations. Panelists further noted that, as many qui tam cases were filed years ago, companies must maintain historic knowledge of their data systems over time in order to develop counterpoints to the relator’s or government’s data.

Download PDF

DISCLAIMER: Because of the generality of this update, the information provided herein may not be applicable in all situations and should not be acted upon without specific legal advice based on particular situations.

© Skadden, Arps, Slate, Meagher & Flom LLP | Attorney Advertising

Written by:

Skadden, Arps, Slate, Meagher & Flom LLP
Contact
more
less

Skadden, Arps, Slate, Meagher & Flom LLP on:

Readers' Choice 2017
Reporters on Deadline

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
Custom Email Digest
- hide

JD Supra Privacy Policy

Updated: May 25, 2018:

JD Supra is a legal publishing service that connects experts and their content with broader audiences of professionals, journalists and associations.

This Privacy Policy describes how JD Supra, LLC ("JD Supra" or "we," "us," or "our") collects, uses and shares personal data collected from visitors to our website (located at www.jdsupra.com) (our "Website") who view only publicly-available content as well as subscribers to our services (such as our email digests or author tools)(our "Services"). By using our Website and registering for one of our Services, you are agreeing to the terms of this Privacy Policy.

Please note that if you subscribe to one of our Services, you can make choices about how we collect, use and share your information through our Privacy Center under the "My Account" dashboard (available if you are logged into your JD Supra account).

Collection of Information

Registration Information. When you register with JD Supra for our Website and Services, either as an author or as a subscriber, you will be asked to provide identifying information to create your JD Supra account ("Registration Data"), such as your:

  • Email
  • First Name
  • Last Name
  • Company Name
  • Company Industry
  • Title
  • Country

Other Information: We also collect other information you may voluntarily provide. This may include content you provide for publication. We may also receive your communications with others through our Website and Services (such as contacting an author through our Website) or communications directly with us (such as through email, feedback or other forms or social media). If you are a subscribed user, we will also collect your user preferences, such as the types of articles you would like to read.

Information from third parties (such as, from your employer or LinkedIn): We may also receive information about you from third party sources. For example, your employer may provide your information to us, such as in connection with an article submitted by your employer for publication. If you choose to use LinkedIn to subscribe to our Website and Services, we also collect information related to your LinkedIn account and profile.

Your interactions with our Website and Services: As is true of most websites, we gather certain information automatically. This information includes IP addresses, browser type, Internet service provider (ISP), referring/exit pages, operating system, date/time stamp and clickstream data. We use this information to analyze trends, to administer the Website and our Services, to improve the content and performance of our Website and Services, and to track users' movements around the site. We may also link this automatically-collected data to personal information, for example, to inform authors about who has read their articles. Some of this data is collected through information sent by your web browser. We also use cookies and other tracking technologies to collect this information. To learn more about cookies and other tracking technologies that JD Supra may use on our Website and Services please see our "Cookies Guide" page.

How do we use this information?

We use the information and data we collect principally in order to provide our Website and Services. More specifically, we may use your personal information to:

  • Operate our Website and Services and publish content;
  • Distribute content to you in accordance with your preferences as well as to provide other notifications to you (for example, updates about our policies and terms);
  • Measure readership and usage of the Website and Services;
  • Communicate with you regarding your questions and requests;
  • Authenticate users and to provide for the safety and security of our Website and Services;
  • Conduct research and similar activities to improve our Website and Services; and
  • Comply with our legal and regulatory responsibilities and to enforce our rights.

How is your information shared?

  • Content and other public information (such as an author profile) is shared on our Website and Services, including via email digests and social media feeds, and is accessible to the general public.
  • If you choose to use our Website and Services to communicate directly with a company or individual, such communication may be shared accordingly.
  • Readership information is provided to publishing law firms and authors of content to give them insight into their readership and to help them to improve their content.
  • Our Website may offer you the opportunity to share information through our Website, such as through Facebook's "Like" or Twitter's "Tweet" button. We offer this functionality to help generate interest in our Website and content and to permit you to recommend content to your contacts. You should be aware that sharing through such functionality may result in information being collected by the applicable social media network and possibly being made publicly available (for example, through a search engine). Any such information collection would be subject to such third party social media network's privacy policy.
  • Your information may also be shared to parties who support our business, such as professional advisors as well as web-hosting providers, analytics providers and other information technology providers.
  • Any court, governmental authority, law enforcement agency or other third party where we believe disclosure is necessary to comply with a legal or regulatory obligation, or otherwise to protect our rights, the rights of any third party or individuals' personal safety, or to detect, prevent, or otherwise address fraud, security or safety issues.
  • To our affiliated entities and in connection with the sale, assignment or other transfer of our company or our business.

How We Protect Your Information

JD Supra takes reasonable and appropriate precautions to insure that user information is protected from loss, misuse and unauthorized access, disclosure, alteration and destruction. We restrict access to user information to those individuals who reasonably need access to perform their job functions, such as our third party email service, customer service personnel and technical staff. You should keep in mind that no Internet transmission is ever 100% secure or error-free. Where you use log-in credentials (usernames, passwords) on our Website, please remember that it is your responsibility to safeguard them. If you believe that your log-in credentials have been compromised, please contact us at privacy@jdsupra.com.

Children's Information

Our Website and Services are not directed at children under the age of 16 and we do not knowingly collect personal information from children under the age of 16 through our Website and/or Services. If you have reason to believe that a child under the age of 16 has provided personal information to us, please contact us, and we will endeavor to delete that information from our databases.

Links to Other Websites

Our Website and Services may contain links to other websites. The operators of such other websites may collect information about you, including through cookies or other technologies. If you are using our Website or Services and click a link to another site, you will leave our Website and this Policy will not apply to your use of and activity on those other sites. We encourage you to read the legal notices posted on those sites, including their privacy policies. We are not responsible for the data collection and use practices of such other sites. This Policy applies solely to the information collected in connection with your use of our Website and Services and does not apply to any practices conducted offline or in connection with any other websites.

Information for EU and Swiss Residents

JD Supra's principal place of business is in the United States. By subscribing to our website, you expressly consent to your information being processed in the United States.

  • Our Legal Basis for Processing: Generally, we rely on our legitimate interests in order to process your personal information. For example, we rely on this legal ground if we use your personal information to manage your Registration Data and administer our relationship with you; to deliver our Website and Services; understand and improve our Website and Services; report reader analytics to our authors; to personalize your experience on our Website and Services; and where necessary to protect or defend our or another's rights or property, or to detect, prevent, or otherwise address fraud, security, safety or privacy issues. Please see Article 6(1)(f) of the E.U. General Data Protection Regulation ("GDPR") In addition, there may be other situations where other grounds for processing may exist, such as where processing is a result of legal requirements (GDPR Article 6(1)(c)) or for reasons of public interest (GDPR Article 6(1)(e)). Please see the "Your Rights" section of this Privacy Policy immediately below for more information about how you may request that we limit or refrain from processing your personal information.
  • Your Rights
    • Right of Access/Portability: You can ask to review details about the information we hold about you and how that information has been used and disclosed. Note that we may request to verify your identification before fulfilling your request. You can also request that your personal information is provided to you in a commonly used electronic format so that you can share it with other organizations.
    • Right to Correct Information: You may ask that we make corrections to any information we hold, if you believe such correction to be necessary.
    • Right to Restrict Our Processing or Erasure of Information: You also have the right in certain circumstances to ask us to restrict processing of your personal information or to erase your personal information. Where you have consented to our use of your personal information, you can withdraw your consent at any time.

You can make a request to exercise any of these rights by emailing us at privacy@jdsupra.com or by writing to us at:

Privacy Officer
JD Supra, LLC
10 Liberty Ship Way, Suite 300
Sausalito, California 94965

You can also manage your profile and subscriptions through our Privacy Center under the "My Account" dashboard.

We will make all practical efforts to respect your wishes. There may be times, however, where we are not able to fulfill your request, for example, if applicable law prohibits our compliance. Please note that JD Supra does not use "automatic decision making" or "profiling" as those terms are defined in the GDPR.

  • Timeframe for retaining your personal information: We will retain your personal information in a form that identifies you only for as long as it serves the purpose(s) for which it was initially collected as stated in this Privacy Policy, or subsequently authorized. We may continue processing your personal information for longer periods, but only for the time and to the extent such processing reasonably serves the purposes of archiving in the public interest, journalism, literature and art, scientific or historical research and statistical analysis, and subject to the protection of this Privacy Policy. For example, if you are an author, your personal information may continue to be published in connection with your article indefinitely. When we have no ongoing legitimate business need to process your personal information, we will either delete or anonymize it, or, if this is not possible (for example, because your personal information has been stored in backup archives), then we will securely store your personal information and isolate it from any further processing until deletion is possible.
  • Onward Transfer to Third Parties: As noted in the "How We Share Your Data" Section above, JD Supra may share your information with third parties. When JD Supra discloses your personal information to third parties, we have ensured that such third parties have either certified under the EU-U.S. or Swiss Privacy Shield Framework and will process all personal data received from EU member states/Switzerland in reliance on the applicable Privacy Shield Framework or that they have been subjected to strict contractual provisions in their contract with us to guarantee an adequate level of data protection for your data.

California Privacy Rights

Pursuant to Section 1798.83 of the California Civil Code, our customers who are California residents have the right to request certain information regarding our disclosure of personal information to third parties for their direct marketing purposes.

You can make a request for this information by emailing us at privacy@jdsupra.com or by writing to us at:

Privacy Officer
JD Supra, LLC
10 Liberty Ship Way, Suite 300
Sausalito, California 94965

Some browsers have incorporated a Do Not Track (DNT) feature. These features, when turned on, send a signal that you prefer that the website you are visiting not collect and use data regarding your online searching and browsing activities. As there is not yet a common understanding on how to interpret the DNT signal, we currently do not respond to DNT signals on our site.

Access/Correct/Update/Delete Personal Information

For non-EU/Swiss residents, if you would like to know what personal information we have about you, you can send an e-mail to privacy@jdsupra.com. We will be in contact with you (by mail or otherwise) to verify your identity and provide you the information you request. We will respond within 30 days to your request for access to your personal information. In some cases, we may not be able to remove your personal information, in which case we will let you know if we are unable to do so and why. If you would like to correct or update your personal information, you can manage your profile and subscriptions through our Privacy Center under the "My Account" dashboard. If you would like to delete your account or remove your information from our Website and Services, send an e-mail to privacy@jdsupra.com.

Changes in Our Privacy Policy

We reserve the right to change this Privacy Policy at any time. Please refer to the date at the top of this page to determine when this Policy was last revised. Any changes to our Privacy Policy will become effective upon posting of the revised policy on the Website. By continuing to use our Website and Services following such changes, you will be deemed to have agreed to such changes.

Contacting JD Supra

If you have any questions about this Privacy Policy, the practices of this site, your dealings with our Website or Services, or if you would like to change any of the information you have provided to us, please contact us at: privacy@jdsupra.com.

JD Supra Cookie Guide

As with many websites, JD Supra's website (located at www.jdsupra.com) (our "Website") and our services (such as our email article digests)(our "Services") use a standard technology called a "cookie" and other similar technologies (such as, pixels and web beacons), which are small data files that are transferred to your computer when you use our Website and Services. These technologies automatically identify your browser whenever you interact with our Website and Services.

How We Use Cookies and Other Tracking Technologies

We use cookies and other tracking technologies to:

  1. Improve the user experience on our Website and Services;
  2. Store the authorization token that users receive when they login to the private areas of our Website. This token is specific to a user's login session and requires a valid username and password to obtain. It is required to access the user's profile information, subscriptions, and analytics;
  3. Track anonymous site usage; and
  4. Permit connectivity with social media networks to permit content sharing.

There are different types of cookies and other technologies used our Website, notably:

  • "Session cookies" - These cookies only last as long as your online session, and disappear from your computer or device when you close your browser (like Internet Explorer, Google Chrome or Safari).
  • "Persistent cookies" - These cookies stay on your computer or device after your browser has been closed and last for a time specified in the cookie. We use persistent cookies when we need to know who you are for more than one browsing session. For example, we use them to remember your preferences for the next time you visit.
  • "Web Beacons/Pixels" - Some of our web pages and emails may also contain small electronic images known as web beacons, clear GIFs or single-pixel GIFs. These images are placed on a web page or email and typically work in conjunction with cookies to collect data. We use these images to identify our users and user behavior, such as counting the number of users who have visited a web page or acted upon one of our email digests.

JD Supra Cookies. We place our own cookies on your computer to track certain information about you while you are using our Website and Services. For example, we place a session cookie on your computer each time you visit our Website. We use these cookies to allow you to log-in to your subscriber account. In addition, through these cookies we are able to collect information about how you use the Website, including what browser you may be using, your IP address, and the URL address you came from upon visiting our Website and the URL you next visit (even if those URLs are not on our Website). We also utilize email web beacons to monitor whether our emails are being delivered and read. We also use these tools to help deliver reader analytics to our authors to give them insight into their readership and help them to improve their content, so that it is most useful for our users.

Analytics/Performance Cookies. JD Supra also uses the following analytic tools to help us analyze the performance of our Website and Services as well as how visitors use our Website and Services:

  • HubSpot - For more information about HubSpot cookies, please visit legal.hubspot.com/privacy-policy.
  • New Relic - For more information on New Relic cookies, please visit www.newrelic.com/privacy.
  • Google Analytics - For more information on Google Analytics cookies, visit www.google.com/policies. To opt-out of being tracked by Google Analytics across all websites visit http://tools.google.com/dlpage/gaoptout. This will allow you to download and install a Google Analytics cookie-free web browser.

Facebook, Twitter and other Social Network Cookies. Our content pages allow you to share content appearing on our Website and Services to your social media accounts through the "Like," "Tweet," or similar buttons displayed on such pages. To accomplish this Service, we embed code that such third party social networks provide and that we do not control. These buttons know that you are logged in to your social network account and therefore such social networks could also know that you are viewing the JD Supra Website.

Controlling and Deleting Cookies

If you would like to change how a browser uses cookies, including blocking or deleting cookies from the JD Supra Website and Services you can do so by changing the settings in your web browser. To control cookies, most browsers allow you to either accept or reject all cookies, only accept certain types of cookies, or prompt you every time a site wishes to save a cookie. It's also easy to delete cookies that are already saved on your device by a browser.

The processes for controlling and deleting cookies vary depending on which browser you use. To find out how to do so with a particular browser, you can use your browser's "Help" function or alternatively, you can visit http://www.aboutcookies.org which explains, step-by-step, how to control and delete cookies in most browsers.

Updates to This Policy

We may update this cookie policy and our Privacy Policy from time-to-time, particularly as technology changes. You can always check this page for the latest version. We may also notify you of changes to our privacy policy by email.

Contacting JD Supra

If you have any questions about how we use cookies and other tracking technologies, please contact us at: privacy@jdsupra.com.

- hide

This website uses cookies to improve user experience, track anonymous site usage, store authorization tokens and permit sharing on social media networks. By continuing to browse this website you accept the use of cookies. Click here to read more about how we use cookies.